Log in
Register
Search|
ElMaestro Hero Denmark, 2018-04-15 14:50 Posting: # 18684 Views: 400 |
|
|
Hi all, story from New York Times. I have seen some cases of the same phenomenon in Europe, when wholesalers have been very forthcoming with supplies of trial material until they are told it is for use as a comparator in a BE trial. Then suddenly there is 'a problem with the supply chain' or some such vague excuse for quickly terminating the call. — if (3) 4 Best regards, ElMaestro "(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018. |
Admin contact
